Results 141 to 150 of about 1,997 (174)

Lomitapide–a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia [PDF]

Current Atherosclerosis Reports, 2020
Purpose of Review: Homozygous familial hypercholesterolemia (HoFH) is a rare, genetic condition characterized by high levels of Low density lipoprotein cholesterol (LDL-C); overt, early-onset atherosclerotic cardiovascular disease (ASCVD); and premature ...
Claudia Stefanutti
exaly   +2 more sources

Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: Five-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER)

Journal of Clinical Lipidology, 2020
International audienceackground: Lomitapide is a lipid-lowering agent indicated as adjunct therapy for homozygous familial hypercholesterolemia (HoFH) in adults.Objective: The Lomitapide Observational Worldwide Evaluation Registry is an international ...
Lukas Makris, Helen Phillips
exaly   +2 more sources

Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia [PDF]

Atherosclerosis Supplements, 2014
The microsomal triglyceride transfer protein (MTP) inhibitor lomitapide is a licenced adjunct to a low-fat diet and other lipid-lowering medication, with or without low-density lipoprotein apheresis, for the treatment of adults with homozygous familial ...
Marina Cuchel, Maurizio Averna, Dirk J Blom   +2 more
exaly   +2 more sources

LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design [PDF]

Journal of Clinical Lipidology, 2016
BackgroundLomitapide is an orally active selective inhibitor of microsomal triglyceride transfer protein approved as adjunctive therapy for homozygous familial hypercholesterolemia (HoFH). The Lomitapide Observational Worldwide Evaluation Registry (LOWER)
Lukas Makris, Zahi A Fayad
exaly   +2 more sources

Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in Italy

Advances in Therapy, 2017
Introduction Homozygous familial hypercholesterolaemia (HoFH) is a rare form of inherited dyslipidemia resistant to conventional cholesterol-lowering medications so that lipoprotein apheresis (LA) is usually required.
Laura Calabresi, Chiara Pavanello, Giovanni B Vigna   +2 more
exaly   +3 more sources

Therapeutic Options for Homozygous Familial Hypercholesterolemia: The Role of Lomitapide

Current Medicinal Chemistry, 2020
Lomitapide (Juxtapid® in US and Lojuxta® in Europe) is the first developed inhibitor of the microsomal triglyceride transfer protein (MTP) approved as a novel drug for the management of homozygous familial hypercholesterolemia (HoFH).
Antonina Giammanco, Davide Noto, Maurizio Averna   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Efficient Delivery of Lomitapide using Hybrid Membrane‐Coated Tetrahedral DNA Nanostructures for Glioblastoma Therapy

Advances in Materials
Glioblastoma (GBM) is the most aggressive and prevalent primary malignant tumor of the central nervous system. Traditional chemotherapy has poor therapeutic effects and significant side effects due to drug resistance, the natural blood‐brain barrier (BBB)
Mingming Song, Jiameng Tian, Li Wang, Shuqi Dong, Kun Fu, Si-Yu Chen, Chang Liu   +6 more
semanticscholar   +1 more source

Metal complex lipid-based nanoparticles deliver metabolism-regulating lomitapide to overcome CTC immune evasion via activating STING pathway.

European journal of pharmaceutics and biopharmaceutics
Activating the cGAS-STING pathway of circulating tumor cell clusters (CTC clusters) represents a promising strategy to mitigate metastases. To fully exploit the potential of cholesterol-regulating agents in activating CTCs' STING levels, we developed a ...
Ni Fan, Feng Zhao, Yuan-Yuan Meng, Li-Qing Chen, Lin Miao, Ping Wang, Manqing Tang, Xuanjun Wu, Ying-Peng Li, Yun-Fei Li, Zhong-Gao Gao   +10 more
semanticscholar   +1 more source

Abstract A038: Lomitapide enhances cytotoxic effects of temozolomide in chemo-resistant glioblastoma

Molecular Cancer Therapeutics
Glioblastoma is the most prevalent and aggressive malignant primary brain tumour in adults, with a median survival following multi-modality therapy of 14.6 months.
Alyona Ivanova, T. Wilson, K. Ghannad-Zadeh, E. Tse, Robert Flick, M. Wu, Sunit Das   +6 more
semanticscholar   +1 more source

Drug repurposing for pancreatic cancer: Lomitapide Mesylate as a potent HK2 inhibitor discovered via virtual screening.

Cellular Signalling
Pancreatic cancer has an early diagnosis rate below 5% and is largely resistant to conventional chemotherapy. Aerobic glycolysis, a metabolic hallmark, drives Epithelial-Mesenchymal Transition (EMT) to promote tumor progression and drug resistance ...
Xin Tan, Ying Zhang, Miao Liu, Fan Wang, Bangwei Huang, Dan Wang, Yue Wang, Jianguo Gao, Zijian Si, Xin-Yi Yang, Li-Bo Liu, Zhaoshen Li, Lianghao Hu, Pengyuan Wang   +13 more
semanticscholar   +1 more source